.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,518,442

« Back to Dashboard

Claims for Patent: 8,518,442

Title:Prolonged release bioadhesive therapeutic systems
Abstract: The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
Inventor(s): Aiache; Jean-Marc (Paris, FR), Costantini; Dominique (Paris, FR), Chaumont; Christine (Paris, FR)
Assignee: BioAlliance Pharma, S.A. (Paris, FR)
Application Number:12/830,090
Patent Claims: 1. A prolonged release bioadhesive therapeutic system comprising: at least one antifungal agent from the broad spectrum azole family, natural proteins representing at least 50% by weight of the antifungal agent and at least 20% by weight of said bioadhesive therapeutic system, between 10% and 20% of a hydrophilic polymer, compression excipients, and between 3.5% and 10% of an alkali metal alkylsulfate.

2. The bioadhesive therapeutic system according to claim 1, wherein said bioadhesive therapeutic system is a mucoadhesive tablet.

3. The bioadhesive therapeutic system according to claim 2, wherein the alkali metal alkylsulfate is sodium lauryl sulfate or sodium diethyl sulfosuccinate.

4. The bioadhesive therapeutic system according to claim 2, in which the alkali metal alkylsulfate is sodium lauryl sulfate.

5. The bioadhesive therapeutic system according to claim 1, wherein the compression excipients contain corn starch.

6. The bioadhesive therapeutic system according to claim 2, in which the antifungal agent is miconazole present in a dose of 10 to 150 mg per tablet.

7. The bioadhesive therapeutic system according to claim 6, further comprising a second agent selected from: a polyene antifungal agent with a different spectrum than the antifungal agent from the broad spectrum azole family; an analgesic; a salivation agent; an antiseptic; a salivary substitute; an anti-inflammatory agent; an antibiotic; thalidomide; and mixtures thereof.

8. The bioadhesive therapeutic system according to claim 7, in which the second active agent is a polyene in a dose of 10 to 100 mg per tablet.

9. The bioadhesive therapeutic system according to claim 7, further comprising 0.1% to 10% by weight of an anesthetic and/or 0.1% to 10% by weight of a salivation agent.

10. The bioadhesive therapeutic system according to claim 4, in which the sodium lauryl sulfate is present in a concentration of 4% to 6%.

11. The bioadhesive therapeutic system according to claim 1, in which the antifungal agent is selected from miconazole, clotrimazole, ketoconazole, fluconazole, itraconazole, isoconazole, econazole, saperconazole, genaconazole, terconazole, butoconazole, tioconazole, oxiconazole, bifonazole, fenticonazole, omoconazole, sertaconazole, and sulconazole.

12. The bioadhesive therapeutic system according to claim 6, in which the miconazole is present in a dose of 25 to 75 mg per tablet.

13. The bioadhesive therapeutic system according to claim 6, in which the miconazole is present in a dose of 50 mg per tablet.

14. The bioadhesive therapeutic system according to claim 8, in which the polyene is present in a dose of 20 to 90 mg.

15. The bioadhesive therapeutic system according to claim 1, in which the natural proteins are a milk protein concentrate.

16. The bioadhesive therapeutic system according to claim 1, in which the hydrophilic polymer is methylhydroxypropylcellulose or metolose.

17. The bioadhesive therapeutic system according to claim 1, in which the antifungal agent is miconazole, the natural proteins are a milk protein concentrate, the hydrophilic polymer is methylhydroxypropylcellulose or metolose, and the alkali metal alkylsulfate is sodium lauryl sulfate.

18. The bioadhesive therapeutic system according to claim 17, in which the miconazole is present in a dose of 10 to 150 mg per tablet.

19. The bioadhesive therapeutic system according to claim 17, in which the miconazole is present in a dose of 25 to 75 mg per tablet.

20. The bioadhesive therapeutic system according to claim 17, in which the miconazole is present in a dose of 50 mg per tablet.

21. The bioadhesive therapeutic system according to claim 17, in which the milk protein concentrate is present in a relative concentration of 15% to 50%.

22. The bioadhesive therapeutic system according to claim 17, in which the milk protein concentrate is present in a relative concentration of 20% to 30%.

23. The bioadhesive therapeutic system according to claim 17, in which the sodium lauryl sulfate is present in a concentration of 4% to 10%.

24. The bioadhesive therapeutic system according to claim 17, in which the sodium lauryl sulfate is present in a concentration of 4% to 6%.

25. The bioadhesive therapeutic system according to claim 17, further comprising corn starch.

26. The bioadhesive therapeutic system according to claim 17, further comprising between 0.1% and 1% of a monohydrate sugar.

27. The bioadhesive therapeutic system according to claim 26, in which the monohydrate sugar is lactose monohydrate.

28. The bioadhesive therapeutic system according to claim 17, further comprising magnesium stearate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc